Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer
NCT00878930 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2011-01-05
Summary
The objectives of this study is to obtain information of Faslodex use in the treatment of breast cancer in the clinical practice in Argentina.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-04-30
- Primary Completion
- 2010-12-31
- Completion
- 2010-12-31
Countries
- Argentina
Study Locations
More Related Trials
-
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
NCT00259090 ·Status: COMPLETED ·Phase: PHASE2
-
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
NCT01992952 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer
NCT01171417 ·Status: COMPLETED
-
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
NCT01300351 ·Status: COMPLETED ·Phase: PHASE3
-
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
NCT00146601 ·Status: COMPLETED ·Phase: PHASE2
-
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
NCT02000193 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.
NCT03236974 ·Status: COMPLETED ·Phase: PHASE1
-
Quality Of Life While Receiving Faslodex
NCT00643513 ·Status: COMPLETED
-
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
NCT00357110 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
NCT00681369 ·Status: COMPLETED
-
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
NCT00543127 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of 500mg of Fulvestrant
NCT00585507 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
NCT00629616 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
NCT00241449 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
NCT02374099 ·Status: TERMINATED ·Phase: PHASE2
-
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
NCT00754325 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
NCT00921115 ·Status: COMPLETED ·Phase: PHASE2
-
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
NCT02437318 ·Status: COMPLETED ·Phase: PHASE3
-
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
NCT00570323 ·Status: COMPLETED ·Phase: PHASE2
-
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
NCT02936206 ·Status: TERMINATED ·Phase: PHASE1
-
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT01953588 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
NCT00305448 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer
NCT00811369 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
NCT00313170 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
NCT00944918 ·Status: COMPLETED ·Phase: PHASE3